Walleye Capital LLC Takes Position in MBX Biosciences, Inc. $MBX

Key Points

• Walleye Capital LLC has acquired a new stake in MBX Biosciences, purchasing 32,490 shares valued at approximately $240,000, representing about 0.10% of the company.
• Several institutional investors, including BNP Paribas and New York State Common Retirement Fund, have also taken new positions in MBX Biosciences, indicating growing interest in the stock.
• Wall Street analysts have a consensus rating of "Buy" for MBX Biosciences, with projections setting an average target price of $37.63.

Walleye Capital LLC acquired a new stake in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 32,490 shares of the company's stock, valued at approximately $240,000. Walleye Capital LLC owned approximately 0.10% of MBX Biosciences as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new position in shares of MBX Biosciences during the fourth quarter valued at approximately $27,000. New York State Common Retirement Fund bought a new position in shares of MBX Biosciences during the first quarter valued at approximately $32,000. Deutsche Bank AG bought a new position in shares of MBX Biosciences during the fourth quarter valued at approximately $80,000. Wells Fargo & Company MN bought a new position in shares of MBX Biosciences during the fourth quarter valued at approximately $108,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of MBX Biosciences during the fourth quarter valued at approximately $117,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on MBX shares. Oppenheimer started coverage on MBX Biosciences in a report on Wednesday, July 16th. They set an "outperform" rating and a $38.00 target price for the company. Mizuho started coverage on MBX Biosciences in a report on Tuesday, August 5th. They set an "outperform" rating and a $38.00 target price for the company. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $37.63.

MBX Biosciences Stock Down 5.4%

MBX traded down $0.62 during trading on Wednesday, reaching $10.80. The stock had a trading volume of 47,749 shares, compared to its average volume of 324,754. The firm has a market capitalization of $362.82 million and a price-to-earnings ratio of -2.38. MBX Biosciences, Inc. has a 1-year low of $4.81 and a 1-year high of $27.50. The stock has a 50 day moving average of $13.21 and a two-hundred day moving average of $10.98.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.